D-dimer as a Predictor of Altered Coagulation in HIV Patients in Nigeria
Gako-hitzak:
HIV, thrombotic event, D-dimer, altered coagulation profile, CD4 count, APTT, PTLaburpena
Summary: Recent medical advances have improved the quality of life and correspondingly reduced the morbidity and mortality associated with HIV infection. However increased life expectancy has led to a relative rise in comorbidities and complications such as alterations in coagulation systems. This study is aimed at the evaluation of D-dimer level as a predictor of thromboembolic risk in HIV patients. A total of 152 HIV positive and negative subjects and control respectively attending the PEPFAR clinic UCH in Ibadan were recruited both for a questionnaire-based survey and a coagulation profile screening. Activated Partial Thromboplastin Time (APTT), Prothrombin Time (PT), D-dimer level the viral load indices of the HIV patients and their CD4 counts were also evaluated. In the subjects, the D-dimer level was significantly higher (193.6 ± 177.00ng/ml) than the controls (118.10 ± 140.58ng/ml) while a significantly lower APTT was also reported (36.22 ± 4.05 seconds) compared to the controls (41.14 ± 8.87 seconds). An evaluation of the coagulation profile in the Highly Active Antiretroviral Therapy (HAART) naive and experienced group revealed only a significant difference (417.4 ± 162.0 versus 268.2 ± 193.5; p value 0.000) in the CD4 counts whilst no significant changes in the coagulation profile. In our study, a higher predisposition to a hypercoagulable state presenting as a short APTT was observed. This finding along with the higher D-dimer level underscores the relevance of the evaluation of this biomarker as an important predictor of thromboembolic event risk.
Erreferentziak
Andrade, A. C. O., & Cotter, B. R. (2006). Endothelial function and cardiovascular diseases in HIV infected patient. Brazilian Journal of Infectious Diseases, 10(2), 139-145.
Armonk, N. (2013). IBM SPSS statistics for Windows: Version.
Essien, E. (1978). Studies in haemostasis--1: The prothrombin time, its standardisation and development of a national thromboplastin standard. Nigerian medical journal: journal of the Nigeria Medical Association, 8(3), 198-202.
Freiberg, M. S., Bebu, I., Tracy, R., So-Armah, K., Okulicz, J., Ganesan, A., . . . Justice, A. C. (2016). D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events. PloS one, 11(4), e0152588.
Funderburg, N. T., Mayne, E., Sieg, S. F., Asaad, R., Jiang, W., Kalinowska, M., . . . Brenchley, J. M. (2010). Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood, 115(2), 161-167.
Glynn, J. R., Caraël, M., Auvert, B., Kahindo, M., Chege, J., Musonda, R., . . . Cities, S. G. o. t. H. o. H. E. i. A. (2001). Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. Aids, 15, S51-S60.
Health, F. M. o. (2010). National guidelines for HIV and AIDS treatment and care in adolescents and adults: Federal Ministry of Health Abuja.
Heit, J. A. (2008). The epidemiology of venous thromboembolism in the community. Arteriosclerosis, thrombosis, and vascular biology, 28(3), 370-372.
Henry, K., Melroe, H., Huebsch, J., Hermundson, J., Levine, C., Swensen, L., & Daley, J. (1998). Severe premature coronary artery disease with protease inhibitors. The Lancet, 351(9112), 1328.
Ifeanyichukwu, M., Ibekilo Sylvester, N., & John Aja, O. B. C. (2016). Activated Partial Thromplastin Time, Prothrombin Time, Thrombin Time and Platelet Count Study in HIV Seropositive Subjects at Nnamdi Azikiwe Teaching Hospital Nnewi. Transl Biomed, 7, 2.
Jacobson, M. C., Dezube, B. J., & Aboulafia, D. M. (2004). Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clinical infectious diseases, 39(8), 1214-1222.
Katz, I. T., & Maughan-Brown, B. (2017). Improved life expectancy of people living with HIV: who is left behind? The lancet HIV, 4(8), e324-e326.
Matchett, M. O., & Ingram, G. (1965). Partial thromboplastin time test with kaolin: Normal range and modifications for the diagnosis of haemophilia and Christmas disease. Journal of clinical pathology, 18(4), 465-471.
MGH Pathology Service; 23rd May 2006. D-Dimer and fibrin degradation products. Available at: www.massgeneral.org/pathology/coagbook/CO002700.htm.
Mkandawire-Valhmu, L., Wendland, C., Stevens, P. E., Kako, P. M., Dressel, A., & Kibicho, J. (2013). Marriage as a risk factor for HIV: Learning from the experiences of HIV-infected women in Malawi. Global Public Health, 8(2), 187-201.
Neuhaus, J., Jacobs Jr, D. R., Baker, J. V., Calmy, A., Duprez, D., La Rosa, A., . . . Ross, M. J. (2010). Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. The Journal of infectious diseases, 201(12), 1788-1795.
Nkengasong, J. N. (2004). Seroprevalence and molecular epidemiology of HIV in Africa. Archives of Ibadan Medicine, 5(1), 4-7.
Nlend, A. E. N., Motaze, A. C. N., Sandie, A., & Fokam, J. (2018). HIV-1 transmission and survival according to feeding options in infants born to HIV-infected women in Yaoundé, Cameroon. BMC pediatrics, 18(1), 69.
Olaleye, O. D. (2004) ‘Virology of Immunodeficiency Virus in Nigeria’, in Symposium organised by the Society of Obstetrics and Gynaecology of Nigeria (SOGON), UCH, Ibadan. Ibadan.
Omoregie, R., Osakue, S., Ihemeje, V., Omokaro, E., & Ogefere, H. (2009). Correlation of CD4 count with platelet count, prothrombin time and activated partial thromboplastin time among HIV patients in Benin City, Nigeria. West Indian Medical Journal, 58(5), 437-440.
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017). Sickle cell disease. New England Journal of Medicine, 376(16), 1561-1573.
Raman, R. T., Manimaran, D., Rachakatla, P., Bharathi, K., Afroz, T., & Sagar, R. (2016). Study of basic coagulation parameters among HIV patients in correlation to CD4 counts and ART status. Journal of clinical and diagnostic research: JCDR, 10(5), EC04.
Riley, R. S., Gilbert, A. R., Dalton, J. B., Pai, S., & McPherson, R. A. (2016). Widely used types and clinical applications of D-dimer assay. Laboratory medicine, 47(2), 90-102.
Saif, M. (2000) ‘Thromboembolism Associated with HIV Infection.’, The Aids Reader, 10(8), pp. 492–496
Saif, M. W., Bona, R., & Greenberg, B. (2001). AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS patient care and STDS, 15(6), 311-320.
Shankar, S. S., & Dubé, M. P. (2004). Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. Cardiovascular toxicology, 4(3), 261-269.
Tene, L., Tagny, C. T., Mintya-Ndoumba, A., Fossi, V. N., & Mbanya, D. (2014). Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis, 25(5), 422.
Tripodi, A. (2011). D-dimer testing in laboratory practice. Clinical chemistry, 57(9), 1256-1262.
Tripodi, A., Chantarangkul, V., Martinelli, I., Bucciarelli, P., & Mannucci, P. M. (2004). A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 104(12), 3631-3634.
Wells, P. S., Brill-Edwards, P., Stevens, P., Panju, A., Patel, A., Douketis, J., and Kearon, C. (1995). A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation, 91(8), 2184-2187.
Zakai, N. A., Ohira, T., White, R., Folsom, A. R., & Cushman, M. (2008). Activated partial thromboplastin time and risk of future venous thromboembolism. The American journal of medicine, 121(3), 231-238.
Deskargak
Argitaratua
Zenbakia
Atala
Lizentzia
Lan hau Creative Commons Aitortu-EzKomertziala-LanEratorririkGabe 4.0 Nazioarteko Lizentziapean dago argitaratuta.
